IL-17C/IL-17RE: Emergence of a Unique Axis in T17 Biology

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Mar 17

PMID 32174926

Citations 37

Authors

Jasper F Nies

Ulf Panzer

Affiliations

Soon will be listed here.

Abstract

Therapeutic targeting of IL-17A and its receptor IL-17RA with antibodies has turned out to be a tremendous success in the treatment of several autoimmune conditions. As the IL-17 cytokine family consists of six members (IL-17A to F), it is intriguing to elucidate the biological function of these five other molecules to identify more potential targets. In the past decade, IL-17C has emerged as quite a unique member of this pro-inflammatory cytokine group. In contrast to the well-described IL-17A and IL-17F, IL-17C is upregulated at very early timepoints of several disease settings. Also, the cellular source of the homodimeric cytokine differs from the other members of the family: Epithelial rather than hematopoietic cells were identified as the producers of IL-17C, while its receptor IL-17RE is expressed on T17 cells as well as the epithelial cells themselves. Numerous investigations led to the current understanding that IL-17C (a) maintains an autocrine loop in the epithelium reinforcing innate immune barriers and (b) stimulates highly inflammatory T17 cells. Functionally, the IL-17C/RE axis has been described to be involved in the pathogenesis of several diseases ranging from infectious and autoimmune conditions to cancer development and progression. This body of evidence has paved the way for the first clinical trials attempting to neutralize IL-17C in patients. Here, we review the latest knowledge about identification, regulation, and function of the IL-17C/IL-17receptor E pathway in inflammation and immunity, with a focus on the mechanisms underlying tissue injury. We also discuss the rationale for the translation of these findings into new therapeutic approaches in patients with immune-mediated disease.

Citing Articles

Novel Inflammatory Biomarkers for Autism Spectrum Disorder Detected by Plasma Olink Proteomics.

Lv T, Wang M, Kui L, Wu J, Xiao Y Children (Basel). 2025; 12(2).

PMID: 40003312 PMC: 11853758. DOI: 10.3390/children12020210.

Nonsense Variant in CYP4F22 Causes Malformation of Corneocyte Lipid Envelopes in a Lamellar Ichthyosis Patient.

Fukaura R, Tanahashi K, Omi M, Takeichi T, Akiyama M Acta Derm Venereol. 2025; 105:adv41072.

PMID: 39907505 PMC: 11812275. DOI: 10.2340/actadv.v105.41072.

Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.

Speeckaert R, Belpaire A, Lambert J, Speeckaert M, van Geel N Immune Netw. 2024; 24(5):e33.

PMID: 39513029 PMC: 11538609. DOI: 10.4110/in.2024.24.e33.

Gelsolin regulates intestinal stem cell regeneration and Th17 cellular function.

Du J, Fang L, Wang Y, Zhao J, Feng Z, Yu Y Cell Commun Signal. 2024; 22(1):524.

PMID: 39472865 PMC: 11520831. DOI: 10.1186/s12964-024-01902-5.

Evaluation of inflammatory biomarkers and their association with anti-SARS-CoV-2 antibody titers in healthcare workers vaccinated with BNT162B2.

Leno-Duran E, Serrano-Conde E, Salas-Rodriguez A, Salcedo-Bellido I, Barrios-Rodriguez R, Fuentes A Front Immunol. 2024; 15:1447317.

PMID: 39247198 PMC: 11377239. DOI: 10.3389/fimmu.2024.1447317.

References

Martin B, Hirota K, Cua D, Stockinger B, Veldhoen M . Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity. 2009; 31(2):321-30. DOI: 10.1016/j.immuni.2009.06.020. View

Jungnickel C, Schmidt L, Bittigkoffer L, Wolf L, Wolf A, Ritzmann F . IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth. Oncogene. 2017; 36(29):4182-4190. DOI: 10.1038/onc.2017.28. View

Peng T, Chanthaphavong R, Sun S, Trigilio J, Phasouk K, Jin L . Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. J Exp Med. 2017; 214(8):2315-2329. PMC: 5551564. DOI: 10.1084/jem.20160581. View

Huang J, Meng S, Hong S, Lin X, Jin W, Dong C . IL-17C is required for lethal inflammation during systemic fungal infection. Cell Mol Immunol. 2015; 13(4):474-83. PMC: 4947823. DOI: 10.1038/cmi.2015.56. View

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P . Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015; 373(26):2534-48. DOI: 10.1056/NEJMoa1505066. View

Huber M, Heink S, Pagenstecher A, Reinhard K, Ritter J, Visekruna A . IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. J Clin Invest. 2012; 123(1):247-60. PMC: 3533283. DOI: 10.1172/JCI63681. View

Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J . Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol. 2006; 177(1):36-9. DOI: 10.4049/jimmunol.177.1.36. View

Ivanov I, de Llanos Frutos R, Manel N, Yoshinaga K, Rifkin D, Sartor R . Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008; 4(4):337-49. PMC: 2597589. DOI: 10.1016/j.chom.2008.09.009. View

Shen F, Li N, Gade P, Kalvakolanu D, Weibley T, Doble B . IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci Signal. 2009; 2(59):ra8. PMC: 2754870. DOI: 10.1126/scisignal.2000066. View

10.

Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C . The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009; 31(4):677-89. DOI: 10.1016/j.immuni.2009.08.020. View

11.

Johansen C, Vinter H, Soegaard-Madsen L, Olsen L, Steiniche T, Iversen L . Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy. Br J Dermatol. 2010; 163(6):1194-204. DOI: 10.1111/j.1365-2133.2010.10036.x. View

12.

Griffiths C, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A . Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51. DOI: 10.1016/S0140-6736(15)60125-8. View

13.

El Malki K, Karbach S, Huppert J, Zayoud M, Reissig S, Schuler R . An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J Invest Dermatol. 2012; 133(2):441-51. DOI: 10.1038/jid.2012.318. View

14.

McInnes I, Mease P, Kirkham B, Kavanaugh A, Ritchlin C, Rahman P . Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(9999):1137-46. DOI: 10.1016/S0140-6736(15)61134-5. View

15.

Chang S, Dong C . A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007; 17(5):435-40. DOI: 10.1038/cr.2007.35. View

16.

Qian Y, Liu C, Hartupee J, Altuntas C, Gulen M, Jane-Wit D . The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol. 2007; 8(3):247-56. DOI: 10.1038/ni1439. View

17.

Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno N, Takahashi K . IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol. 2007; 179(10):7128-36. DOI: 10.4049/jimmunol.179.10.7128. View

18.

Huang J, Yuan Q, Zhu H, Yin L, Hong S, Dong Z . IL-17C/IL-17RE Augments T Cell Function in Autoimmune Hepatitis. J Immunol. 2016; 198(2):669-680. DOI: 10.4049/jimmunol.1600977. View

19.

Feagan B, Sandborn W, Gasink C, Jacobstein D, Lang Y, Friedman J . Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375(20):1946-1960. DOI: 10.1056/NEJMoa1602773. View

20.

Yamaguchi S, Nambu A, Numata T, Yoshizaki T, Narushima S, Shimura E . The roles of IL-17C in T cell-dependent and -independent inflammatory diseases. Sci Rep. 2018; 8(1):15750. PMC: 6200819. DOI: 10.1038/s41598-018-34054-x. View